{"id":"cxcr4","name":"CXCR4","symbol":"CXCR4","route":"/targets/cxcr4/","asOf":"2026-09-08","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2561","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000121966","uniprot":"https://www.uniprot.org/uniprotkb/P61073/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P61073","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2107","open-targets":"https://platform.opentargets.org/target/ENSG00000121966","civic":"https://civicdb.org/genes/7852/summary","oncokb":"https://www.oncokb.org/gene/CXCR4","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CXCR4","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=CXCR4","depmap":"https://depmap.org/portal/gene/CXCR4?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000121966-CXCR4","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/7852","omim":"https://www.omim.org/entry/162643"}],"products":[{"id":"mavorixafor","name":"Mavorixafor","status":"approved","modality":"Oral CXCR4 antagonist","route":"/drugs/mavorixafor/"},{"id":"plerixafor","name":"Plerixafor","status":"approved","modality":"Small-molecule CXCR4 antagonist (stem cell mobiliser)","route":"/drugs/plerixafor/"}],"trials":[{"id":"nct01767714","name":"Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation","nct":"NCT01767714","phase":"3","status":"completed"},{"id":"nct01301963","name":"Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide","nct":"NCT01301963","phase":"3"},{"id":"nct00103662","name":"Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients","nct":"NCT00103662","phase":"3","status":"completed"},{"id":"nct04274738","name":"A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4","nct":"NCT04274738","phase":"1","status":"completed"},{"id":"nct02823405","name":"X4P-001 and Pembrolizumab in Patients With Advanced Melanoma","nct":"NCT02823405","phase":"1","status":"completed"}],"pathways":[],"companies":["biolinerx","sanofi","x4-pharmaceuticals"],"keyPapers":["paper-treon-blood","paper-feig-cxcl12-fap-cafs-t-cell-exclusion-pnas-2013"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}